Aktieanalys

Ascelia Pharma: Time for take-off - Redeye

{newsItem.title}

Redeye Publicerad: 20 May 08:21

Ascelia’s Q1 result was minor compared to the recent SPARKLE success. Ascelia is preparing for submission by mid-2025, and Ascelia’s cost base was contained. Our Base Case is SEK 17 (Bull SEK 45 and Bear SEK 6).

Länk till analysen i sin helhet: https://www.redeye.se/research/1009153/ascelia-pharma-time-for-take-off?utm_source=finwire&utm_medium=RSS

Nyheter om Ascelia Pharma

Läses av andra just nu

Om aktien Ascelia Pharma

Senaste nytt